Avacta Life Sciences Limited
  • About
  • Therapeutics
    • Therapeutics
    • Affimer®
    • pre|CISIONTM
    • Pipeline
    • Partnering
    • News
  • Diagnostics
  • Investors
  • News
  • Careers
  • Contact
  • About
    • About Avacta
    • People
    • Scientific Resources
    • Intellectual Property
    • Virtual tour
  • Therapeutics
    • Therapeutics
    • Affimer®
    • pre|CISIONTM
    • Pipeline
    • Partnering
    • News
  • Diagnostics
    • Diagnostics
    • Products
    • Affimer®
    • Key benefits
    • Partnering
    • Resources
    • News
  • Investors
    • Investors
    • CEO Welcome
    • Key information
    • Corporate Governance
    • Documents & Presentations
    • Share price
    • RNS News
  • News
  • Careers
    • CEO Welcome
    • Job vacancies
    • About Avacta
    • Benefits of working at Avacta
  • Contact
  • About
    • About Avacta
    • People
    • Scientific Resources
    • Intellectual Property
    • Virtual tour
  • Therapeutics
    • Therapeutics
    • Affimer®
    • pre|CISIONTM
    • Pipeline
    • Partnering
    • News
  • Diagnostics
    • Diagnostics
    • Products
    • Affimer®
    • Key benefits
    • Partnering
    • Resources
    • News
  • Investors
    • Investors
    • CEO Welcome
    • Key information
    • Corporate Governance
    • Documents & Presentations
    • Share price
    • RNS News
  • News
  • Careers
    • CEO Welcome
    • Job vacancies
    • About Avacta
    • Benefits of working at Avacta
  • Contact
Home News Therapeutics
filter by: view all | Blogs | Diagnostics | Investors | Therapeutics

Therapeutics

18 Feb 2021

Phase I Clinical Trial Authorisation for AVA6000 Approved by MHRA

Investors | Therapeutics
01 Feb 2021

AffyXell $7.3 Million Series A Financing

Investors | Therapeutics
07 Jan 2021

License Agreement with POINT Biopharma Inc

Investors | Therapeutics
23 Dec 2020

Submission of Clinical Trial Application for AVA6000 Pro-doxorubixin

Investors | Therapeutics
27 Oct 2020

ShareBuyers Interview with Alastair Smith

Diagnostics | Investors | Therapeutics
18 Aug 2020

Avacta and LG Chem Life Sciences Expand Partnership

Investors | Therapeutics
11 Aug 2020

Avacta Appoints Therapeutics Chief Development Officer

Investors | Therapeutics
30 Jul 2020

Innovations in neutralising therapies

Blogs | Therapeutics
29 Jul 2020

Expansion of Partnership with Daewoong Pharmaceutical to Include COVID-19 Neutralising Affimer Therapy

Investors | Therapeutics
18 Jun 2020

Update on Affimer® Therapy for COVID-19 Infection

Investors | Therapeutics

Posts navigation

Older posts
Avacta Life Sciences Limited
  • Terms of Use
  • Terms & Conditions
  • Privacy Policy
  • Intellectual Property
  • Returns & cancellations policy
  • Corporate Responsibility
  • Contact Us
  • Avacta Animal Health

Avacta Life Sciences Ltd

Unit 20, Ash Way
Thorp Arch Estate
Wetherby
LS23 7FA
+44 (0)1904 21 7070

virtual tour
email

Avacta Cambridge

Unit B, 1 Lion Works
Station Road East
Whittlesford
Cambridge
CB22 4WL

virtual tour
email

FTI Consulting

200 Aldersgate
Aldersgate Street
London
EC1A 4HD

+44 (0)20 3727 1000

email

Twitter | Linkedin

©2021 Avacta Life Sciences Limited. Registered company no. 06605196.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok